OVERSEA CHINESE BANKING Corp Ltd Buys Shares of 7,080 IQVIA Holdings Inc. $IQV

OVERSEA CHINESE BANKING Corp Ltd purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 7,080 shares of the medical research company’s stock, valued at approximately $1,368,000.

Several other large investors also recently made changes to their positions in the stock. Apella Capital LLC raised its stake in shares of IQVIA by 5.1% in the 1st quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock valued at $211,000 after acquiring an additional 58 shares in the last quarter. Quadrant Capital Group LLC boosted its position in IQVIA by 1.3% during the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock worth $1,080,000 after purchasing an additional 60 shares during the period. Private Advisor Group LLC grew its holdings in IQVIA by 1.0% during the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after purchasing an additional 63 shares during the last quarter. Breakwater Capital Group grew its holdings in IQVIA by 3.2% during the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after purchasing an additional 64 shares during the last quarter. Finally, Keybank National Association OH raised its position in shares of IQVIA by 0.7% in the fourth quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after purchasing an additional 67 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a report on Thursday, July 9th. Robert W. Baird boosted their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Finally, HSBC reaffirmed a “buy” rating and issued a $240.00 price target on shares of IQVIA in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Trading Up 1.6%

Shares of IQV opened at $260.17 on Friday. The stock’s 50-day moving average price is $213.32 and its 200 day moving average price is $187.52. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $42.82 billion, a price-to-earnings ratio of 32.28, a P/E/G ratio of 2.17 and a beta of 1.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $260.40.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter last year, the company earned $2.81 EPS. The company’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its board has initiated a stock buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.

Insider Transactions at IQVIA

In related news, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at $317,143.96. This represents a 57.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last ninety days. 1.70% of the stock is owned by company insiders.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.